Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I Dose Escalation Trial of AZD1775 in Combination with Gemcitabine and Radiation For Patients with Unresectable Pancreatic Adenocarcinoma

Summary

The investigators' long-term goal in this phase I study is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by administering it concurrently with the Wee1 inhibitor AZD1775.

General Information

NCT#: NCT02037230
Study ID: UMCC-2013-094
Trial Phase: Phase I

Trial Sponsor: University of Michigan Cancer Center
Therapies Used in This Trial: Gemcitabine, Radiation Therapy, AZD1775

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search